It was a good week for Biogen Idec Inc. shares after US regulators OK’d its first pill to treat multiple sclerosis, cementing the Weston company’s dominance in MS treatments. The FDA approved Tecfidera as a “first-line” treatment, meaning doctors can prescribe it for newly diagnosed patients and those already taking MS drugs. Analysts say Tecfidera potentially could become one of the top-selling prescription drugs of all time by the end of the decade.
Biogen Idec jumps on Techfidera approval
You've reached the limit of 10 free articles a month
Stay informed with unlimited access to Boston’s trusted news source.
- High-quality journalism from the region’s largest newsroom
- Convenient access across all of your devices
- Today’s Headlines daily newsletter
- Subscriber-only access to exclusive offers, events, contests, eBooks, and more
- Less than $1 a week